Contact
searchSearch
HMP Global

Nonradiographic Axial Spondyloarthritis Topic Center

Featured Article

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Earlier Treatment May Improve Outcomes in Patients With Nonradiographic Axial Spondyloarthritis
10/14/2022
Jolynn Tumolo
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs...
10/14/2022
First Report Managed Care

Newsfeed

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Outpatient Epcoritamab Dosing Feasible in R/R DLBCL, Study Finds
04/20/2026
Grace Taylor, MS, MA
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study,...
04/20/2026
First Report Managed Care
News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Real-World Data Show Semaglutide’s Impact on Health Care Utilization and Medical Costs for Patients With OW/OB
04/17/2026
Rebecca Amrick
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a...
04/17/2026
First Report Managed Care
News
Improving RVU Compensation Models to be More Equitable for Transplant Nephrologists
04/16/2026
Rebecca Amrick
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines...
04/16/2026
First Report Managed Care
News
Mail-Based FIT Program Increases CRC Screening in a Value-Based Care System
04/13/2026
Rebecca Amrick
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health initiative using mail-in fecal immunochemical tests (FIT) shows a slight increase in patient participation in colorectal cancer (CRC) screenings and prevention.
A large, system-wide health...
04/13/2026
First Report Managed Care
News
What Real-World Data Reveal About R/R DLBCL Care
04/13/2026
Rebecca Amrick
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) has led to a lack of cohesion and disordered care for later lines of therapy.
A high variety of treatments...
04/13/2026
First Report Managed Care
News
Delays in Early-Stage NSCLC Surgery Linked to Systemic and Equity Gaps in Patients
04/13/2026
Rebecca Amrick
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among patients with early-stage non–small cell lung cancer (NSCLC) lead to patients experiencing delayed surgical resection beyond the recommended 8-week window from diagnosis.
Systemic and equity gaps among...
04/13/2026
First Report Managed Care
News
Epcoritamab Plus R2 Maintains Quality of Life in R/R Follicular
04/10/2026
Hannah Musick
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and lenalidomide (R2) improved response rates in relapsed or refractory (R/R) follicular lymphoma while maintaining health-related quality of life despite higher rates of adverse events.
Epcoritamab plus rituximab and...
04/10/2026
First Report Managed Care
Behind the Bill
CMS Proposes FY 2027 Skilled Nursing Facility Payment and Quality Updates
04/10/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare & Medicaid Services (CMS) has proposed its rule for the Fiscal Year (FY) 2027 Skilled Nursing Facility Prospective Payment System (SNF PPS), which introduces a modest payment increase alongside key updates to quality...
The Centers for Medicare &...
04/10/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use